The following is an interesting post from the Apothecurry blog on the topic of the global R&D convention proposed by an expert working group of the World Health Organization. In theory, the convention would complement the existing patent system and be of great benefit to patients around the world. In practice, it's easy to imagine how this ideal system could get derailed. The WHO's executive board is scheduled to revisit the idea (and perhaps consider alternatives) in 2013.
Patients and Patents's blog
An interesting op-ed from the Seattle Times highlighting the importance of ensuring strong IP protections in the Trans-Pacific Partnership for biotech companies as well as global health.
Central to the success of the TPP is the establishment of strong intellectual property rights. Strong property rights allow companies to invest in drug research and development and retain high-quality biomedical jobs in California and across the United States.
A 21st century TPP agreement with strong intellectual property protections is essential. This Trans Pacific region is vital to the U.S. economy. It's home to 40 percent of the world's population and 56 percent of global GDP. The region is the third largest export market for American goods, totaling $618 billion in 2009.
The trade agreement under negotiation aims to support the creation and retention of jobs in the Trans-Pacific Partnership countries, strengthen Asia-Pacific relations, and eventually create a free-trade area across the region.
An interesting program by the US Patent and Trade Office to provide business incentives for patent holders to tackle the world's most pressing challenges.
An interesting op-ed by John Castellani, PhRMA CEO, about the proposed intellectual property provisions in the Trans Pacific Partnership (TPP) trade agreement, innovation and access to medicines. Without appropriate intellectual property protection, further innovations and needed research, progress could be slowed and in some areas stopped — and it is patients who will lose out.
Today, 13 pharmaceutical companies, the U.S., U.K. and U.A.E governments, the Bill & Melinda Gates Foundation, the World Bank and other global health organisations announced a new, coordinated push to accelerate progress toward eliminating or controlling 10 neglected tropical diseases (NTDs) by the end of the decade.
Uniting efforts with NTD-endemic countries, partners pledged to bring a unique focus to defeating these diseases and to work together to improve the lives of the 1.4 billion people worldwide affected by NTDs, most of whom are among the world’s poorest.
According to a report by The Moscow Times, many European leaders have recently agreed to cooperate in the fight against counterfeit medicines:
The following report published in The Guardian today provides encouraging global health news -- GSK's new vaccine against malaria has been shown to halve the risk of malaria.
Millions of small children's lives could be saved by a new vaccine that has been shown to halve the risk of malaria in the first large-scale trials across seven African countries.